Sotera Health Co (Sotera Health Co) Forward PE Ratio : 16.08 (As of Apr. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sotera Health Co Forward PE Ratio?

Sotera Health Co's Forward PE Ratio for today is 16.08.

Sotera Health Co's PE Ratio without NRI for today is 16.77.

Sotera Health Co's PE Ratio for today is 64.39.

Sotera Health Co Forward PE Ratio Historical Data

The historical data trend for Sotera Health Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sotera Health Co Forward PE Ratio Chart

Sotera Health Co Annual Data

Trend

2020-12

2021-12

2022-12

2023-12

2024-04

Forward PE Ratio

36.50

22.94

7.86

20.04

15.82

Sotera Health Co Quarterly Data
	2020-12	2021-03	2021-06	2021-09	2021-12	2022-03	2022-06	2022-09	2022-12	2023-03	2023-06	2023-09	2023-12	2024-03
Forward PE Ratio	36.50	29.85	29.50	25.13	22.94	22.42	21.23	6.44	7.86	22.12	23.53	16.10	20.04	16.67

Competitive Comparison of Sotera Health Co's Forward PE Ratio

For the Diagnostics & Research subindustry, Sotera Health Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sotera Health Co's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sotera Health Co's Forward PE Ratio falls into.

Sotera Health Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Sotera Health Co (NAS:SHC) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Sotera Health Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sotera Health Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Sotera Health Co (Sotera Health Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sotera Health Co (NAS:SHC) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

9100 South Hills Boulevard, Suite 300, Broadview Heights, OH, USA, 44147

Website

https://investors.soterahealth.com

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.

Executives

Jonathan M. Lyons	officer: Sr. Vice President, CFO	9100 SOUTH HILLS BLVD., SUITE 300, BROADVIEW HEIGHTS OH 44147
Robert Brown Knauss	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Alexander Dimitrief	officer: SVP, General Counsel and Sec.	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Michael F Biehl	officer: Interim CFO	5885 LANDBROOK DRIVE SUITE 205, CLEVELAND OH 44124
Terry Hammons	officer: SVP, GC and Secretary	C/O SIMPSON MANUFACTURING CO., INC., 5956 W LAS POSITAS BLVD, PLEASANTON CA 94588
Michael P Rutz	officer: President of Sterigenics	8755 WEST HIGGINS ROAD, SUITE 500, CHICAGO IL 60631
Wp Xi Partners, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, 450 LEXINGTON AVENUE NY 10017
Warburg Pincus & Co.	director, 10 percent owner	450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147
Gtcr Fund Xi/a Lp	director, 10 percent owner	300 NORTH LASALLE STREET, SUITE 5600, CHICAGO IL 60654
Matthew J Klaben	officer: SVP, GC and Secretary	ONE INFINITY CORPORATE CENTRE DRIVE, SUITE 300, GARFIELD HEIGHTS OH 44125
Petras Michael B. Jr.	director, officer: Chairman & CEO	9100 SOUTH HILLS BLVD, SUITE 300, BROADVIEW HEIGHTS OH 44147
Stephanie Geveda	director	450 LEXINGTON AVENUE, C/O WARBURG PINCUS LLC, NEW YORK NY 10017
Sean Laurence Cunningham	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Scott J. Leffler	officer: CFO and Treasurer	C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067